The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy.

Abstract

OBJECTIVE:

To evaluate the efficacy of levonorgestrel intrauterine systems (LNG-IUS) in obese women with AUB on anticoagulant therapy.

DESIGN:

Prospective observational case series (Canadian Task Force Classification II-3).

SETTING:

University affiliated teaching hospital.

PATIENTS:

Premenopausal women on Warfarin therapy.

INTERVENTIONS:

From January 2002 through January 2007, 10 women were identified from the senior author's clinical practice (G.A.V.). After clinical assessment, including Papanicolaou smear, endometrial biopsy, and pelvic sonography, the LNG-IUS was placed to treat their AUB.

MEASUREMENTS AND MAIN RESULTS:

The median and range of age, parity, and body mass index were 45 years (34-49), 1 (0-4), and 38 kg/m(2) (26-52), respectively. All women were receiving warfarin therapy (4-12.5 mg/d) for previous venous thromboembolism. Some patients had additional comorbid conditions and were at high risk for traditional medical or surgical therapies. After placement of the LNG-IUS, all women reported menstrual reduction at 3 and 6 months. By 12 months, 1 woman with large fibroids expelled the LNG-IUS and was treated with transfemoral uterine artery embolization. Two women had amenorrhea, and 7 had hypomenorrhea. At 2 to 5 years, 1 woman expelled the LNG-IUS and hysterectomy indicated extensive adenomyosis in a 195-g uterus, and 1 woman had hysteroscopic endometrial ablation, 4 were menopausal, 2 had amenorrhea, and 1 had hypomenorrhea. In the 5 women with uterine fibroids measuring 4.2 to 147 cm(3), the fibroids were reduced in volume by approximately 75% in 2, were no longer detectable in 1, were subsequently shown to be adenomyoma in 1, and required uterine artery embolization in 1.

CONCLUSION:

In properly assessed and selected obese, premenopausal women with AUB receiving warfarin therapy and at high risk for traditional therapies, the LNG-IUS was an effective treatment in 70% of patients.

• Authors: George A Vilos, Valentin Tureanu, Meivys Garcia, Basim Abu-Rafea
• Journal: Journal of minimally invasive gynecology (J Minim Invasive Gynecol) 2009 Jul-Aug Vol. 16 Issue 4 Pg. 480-4 ISSN: 1553-4650 [Print] United States
• PMID: 19573825 (Publication Type: Journal Article)

Chemical References

• Anticoagulants
• Contraceptives, Oral, Synthetic
• Warfarin
• Levonorgestrel

Topics

• Adult
• Anticoagulants (therapeutic use)
• Contraceptives, Oral, Synthetic (therapeutic use)
• Female
• Humans
• Intrauterine Devices, Medicated
• Levonorgestrel (therapeutic use)
• Metrorrhagia (complications, drug therapy)
• Middle Aged
• Obesity (complications)
• Prospective Studies
• Thrombosis (complications, prevention & control)
• Warfarin (therapeutic use)